MX2010004314A - Compounds for inhibiting ksp kinesin activity. - Google Patents
Compounds for inhibiting ksp kinesin activity.Info
- Publication number
- MX2010004314A MX2010004314A MX2010004314A MX2010004314A MX2010004314A MX 2010004314 A MX2010004314 A MX 2010004314A MX 2010004314 A MX2010004314 A MX 2010004314A MX 2010004314 A MX2010004314 A MX 2010004314A MX 2010004314 A MX2010004314 A MX 2010004314A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds
- ksp kinesin
- kinesin activity
- inhibiting ksp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to compounds of Formula (I), below, (wherein X, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>27</sup>, R<sup>28</sup>, p, E, ring A, and ring B are as defined herein). The present invention also relates to compositions (including pharmaceutically acceptable compositions) comprising these compounds, alone and in combination with one or more additional therapeutic agents, and to methods for their use in inhibiting KSP kinesin activity, and for treating cellular proliferative diseases or disorders associated with KSP kinesin activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98679907P | 2007-11-09 | 2007-11-09 | |
PCT/US2008/080176 WO2009061596A1 (en) | 2007-11-09 | 2008-10-16 | Compounds for inhibiting ksp kinesin activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010004314A true MX2010004314A (en) | 2010-04-30 |
Family
ID=40254344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010004314A MX2010004314A (en) | 2007-11-09 | 2008-10-16 | Compounds for inhibiting ksp kinesin activity. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2215064A1 (en) |
JP (1) | JP2011503076A (en) |
KR (1) | KR20100075508A (en) |
CN (1) | CN101952255A (en) |
AR (1) | AR068889A1 (en) |
AU (1) | AU2008325025A1 (en) |
CA (1) | CA2702990A1 (en) |
CL (1) | CL2008003062A1 (en) |
IL (1) | IL205181A0 (en) |
MX (1) | MX2010004314A (en) |
PE (1) | PE20090968A1 (en) |
TW (1) | TW200922559A (en) |
WO (1) | WO2009061596A1 (en) |
ZA (1) | ZA201002700B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2702922C (en) * | 2007-10-19 | 2018-01-16 | Schering Corporation | Spiro-condensed 1,3,4-thiadiazole derivatives for inhibiting ksp kinesin activity |
DE102008001932A1 (en) * | 2008-05-21 | 2009-11-26 | Bayer Cropscience Ag | Substituted spiroisoxazolines |
MX2016012097A (en) * | 2014-03-20 | 2017-04-27 | Capella Therapeutics Inc | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer. |
US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5336470B2 (en) * | 1971-08-09 | 1978-10-03 | ||
CA2478068C (en) * | 2002-03-08 | 2011-02-08 | Merck & Co., Inc. | Dihydropyrazole compounds useful for treating or preventing cancer |
US7449486B2 (en) * | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
CN101155583B (en) * | 2005-04-07 | 2011-01-19 | 默沙东公司 | Mitotic kinesin inhibitors |
-
2008
- 2008-10-16 CA CA2702990A patent/CA2702990A1/en not_active Abandoned
- 2008-10-16 JP JP2010533142A patent/JP2011503076A/en active Pending
- 2008-10-16 EP EP08847176A patent/EP2215064A1/en not_active Withdrawn
- 2008-10-16 MX MX2010004314A patent/MX2010004314A/en not_active Application Discontinuation
- 2008-10-16 AU AU2008325025A patent/AU2008325025A1/en not_active Abandoned
- 2008-10-16 TW TW097139719A patent/TW200922559A/en unknown
- 2008-10-16 KR KR1020107008486A patent/KR20100075508A/en not_active Application Discontinuation
- 2008-10-16 WO PCT/US2008/080176 patent/WO2009061596A1/en active Application Filing
- 2008-10-16 CN CN2008801214797A patent/CN101952255A/en active Pending
- 2008-10-16 AR ARP080104503A patent/AR068889A1/en not_active Application Discontinuation
- 2008-10-16 CL CL2008003062A patent/CL2008003062A1/en unknown
- 2008-10-16 PE PE2008001777A patent/PE20090968A1/en not_active Application Discontinuation
-
2010
- 2010-04-16 ZA ZA2010/02700A patent/ZA201002700B/en unknown
- 2010-04-18 IL IL205181A patent/IL205181A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009061596A1 (en) | 2009-05-14 |
EP2215064A1 (en) | 2010-08-11 |
IL205181A0 (en) | 2010-11-30 |
AU2008325025A1 (en) | 2009-05-14 |
CA2702990A1 (en) | 2009-05-14 |
PE20090968A1 (en) | 2009-07-13 |
ZA201002700B (en) | 2010-12-29 |
AR068889A1 (en) | 2009-12-16 |
JP2011503076A (en) | 2011-01-27 |
CN101952255A (en) | 2011-01-19 |
KR20100075508A (en) | 2010-07-02 |
CL2008003062A1 (en) | 2010-02-19 |
TW200922559A (en) | 2009-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010004312A (en) | Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity. | |
TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
TW200700422A (en) | Compounds for inhibiting ksp kinesin activity | |
GEP20125538B (en) | 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases | |
TN2012000062A1 (en) | Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer | |
EP2512479A4 (en) | Methods and compositions for treating peripheral vascular disease | |
GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
NZ592425A (en) | Isoindoline compounds for use in the treatment of cancer | |
HK1095139A1 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
IL176110A0 (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
HK1097189A1 (en) | Cannabinoid receptor ligands | |
IL175714A0 (en) | Quinazolinone compounds as anticancer agents | |
MX2009003157A (en) | Therapeutic pyrazolyl thienopyridines. | |
TW200700066A (en) | Compounds for inhibiting ksp kinesin activity | |
DE602004011394D1 (en) | Thiazolderivate | |
TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
MX2012004848A (en) | Tricyclic heterocyclic compounds. | |
TW200611695A (en) | Pyrrolopyridine derivatives | |
MXPA06009475A (en) | Quinazoline derivatives and therapeutic use thereof. | |
CR20200286A (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
MX2010009625A (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40. | |
TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
MX2009009238A (en) | Novel phosphodi esterase inhibitors. | |
AR060019A1 (en) | PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER | |
MX2007007027A (en) | Piperazinyl pyridine derivatives as anti-obesity agents. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |